PD-1 antibody (AA 101-288)

Catalog No. ABIN3032311

This Rabbit Polyclonal antibody specifically detects PD-1 in IHC (p). It exhibits reactivity toward Human.

Quick Overview for PD-1 antibody (AA 101-288) (ABIN3032311)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PD-1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-PD-1 Antibody

Binding Specificity: AA 101-288

Purpose: PD1 Antibody

Purification: Antigen affinity

Immunogen: Human partial recombinant protein (AA 101-288) was used as the immunogen for this PD1 antibody.

Isotype: IgG

Application Details

Application Notes: The stated application concentrations are suggested starting points. Titration of the PD1 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the PD1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: PD1

Background: PDCD1 (Programmed cell death 1), also called PD1, encodes a cell surface receptor that is a member of the B7 superfamily involved in immunomodulation. This gene is mapped to 2q37.3. PDCD1 acts as an inhibitory molecule on T cells after interacting with its ligands PDL1 and PDL2. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. Using flow cytometric analysis, it has been found that expression of PDCD1 was upregulated on CD16-positive and CD16-negative monocytes, but not on dendritic cells, in viremic HIV-positive patients, but not in highly active antiretroviral therapy (HAART)-treated HIV-positive patients. Upregulation in monocytes was induced by microbial Toll-like receptor ligands and inflammatory cytokines.

Pathways: Cancer Immune Checkpoints